New Genetic Markers of Skin T-Cell Lymphoma Treatment
Abstract
1. Introduction
2. Materials and Methods
3. Statistical Analysis
4. Results
5. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dummer, R.; Vermeer, M.H.; Scarisbrick, J.J.; Kim, Y.H.; Stonesifer, C.; Tensen, C.P.; Geskin, L.J.; Quaglino, P.; Ramelyte, E. Cutaneous T cell lymphoma. Nat. Rev. Dis. Prim. 2021, 26, 61. [Google Scholar] [CrossRef]
- Lee, H. Mycosis fungoides and Sézary syndrome. Blood Res. 2023, 58, 66–82. [Google Scholar] [CrossRef]
- Kamijo, H.; Miyagaki, T. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy. Curr. Treat. Options Oncol. 2021, 22, 10. [Google Scholar] [CrossRef]
- Schmidt, J.; Bonzheim, I.; Steinhilber, J.; Montes-Mojarro, I.A.; Ortiz-Hidalgo, C.; Klapper, W.; Fend, F.; Quintanilla-Martínez, L. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK-anaplastic large-cell lymphoma. Lab. Investig. 2017, 97, 1095–1102. [Google Scholar] [CrossRef]
- Sakamoto, M.; Miyagaki, T.; Kamijo, H.; Oka, T.; Boki, H.; Takahashi-Shishido, N.; Suga, H.; Sugaya, M.; Sato, S. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma. Int. J. Mol. Sci. 2021, 22, 7889. [Google Scholar] [CrossRef]
- Kataoka, H.; DeCastro, R.; Zucker, S. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res. 1993, 53, 3154–3158. [Google Scholar]
- Liotta, L.A.; Tryggvason, K.; Garbisa, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284, 67–68. [Google Scholar] [CrossRef]
- Vasku, A.; Vasku, J.B.; Necas, M.; Vasku, V. Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage. J. Biomed. Biotechnol. 2010, 2010, 805907. [Google Scholar] [CrossRef] [PubMed]
- Wu, L.S.; Li, F.F.; Sun, L.D.; Li, D.; Su, J.; Kuang, Y.H.; Chen, G.; Chen, X.P.; Chen, X. A miRNA-492 binding-site polymorphism in BSG (basigin) confers risk to psoriasis in central south Chinese population. Hum. Genet. 2011, 130, 749–757. [Google Scholar] [CrossRef] [PubMed]
- Alcina, A.; Abad-Grau Mdel, M.; Fedetz, M.; Izquierdo, G.; Lucas, M.; Fernández, O.; Ndagire, D.; Catalá-Rabasa, A.; Ruiz, A.; Gayán, J.; et al. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS ONE 2012, 7, e29819. [Google Scholar] [CrossRef] [PubMed]
- Benešová, Y.; Vašků, A.; Stourač, P.; Hladíková, M.; Fiala, A.; Bednařík, J. Association of HLA-DRB1*1501 tagging rs3135388 gene polymorphism with multiple sclerosis. J. Neuroimmunol. 2013, 255, 92–96. [Google Scholar] [CrossRef]
- Hebbring, S.J.; Schrodi, S.J.; Ye, Z.; Zhou, Z.; Page, D.; Brilliant, M.H. A PheWAS approach in studying HLA-DRB1*1501. Genes. Immun. 2013, 14, 187–191. [Google Scholar] [CrossRef]
- Brazzelli, V.; Rivetti, N.; Badulli, C.; Carugno, A.; Grasso, V.; De Silvestri, A.; Martinetti, M.; Borroni, G. Immunogenetic factors in mycosis fungoides: Can the HLA system influence the susceptibility and prognosis of the disease? Long-term follow-up study of 46 patients. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 1732–1737. [Google Scholar] [CrossRef] [PubMed]
- Gilson, D.; Whittaker, S.J.; Child, F.J.; Scarisbrick, J.; Illidge, T.M.; Parry, E.J.; Mohd Mustapa, M.F.; Exton, L.S.; Kanfer, E.; Rezvani, K.; et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br. J. Dermatol. 2019, 180, 496–526. [Google Scholar] [CrossRef] [PubMed]
- Kempf, W.; Zimmermann, A.K.; Mitteldorf, C. Cutaneous lymphomas-An update 2019. Hematol. Oncol. 2019, 37 (Suppl. S1), 43–47. [Google Scholar] [CrossRef] [PubMed]
- Kempf, W.; Mitteldorf, C. Cutaneous T-cell lymphomas-An update 2021. Hematol. Oncol. 2021, 39 (Suppl. S1), 46–51. [Google Scholar] [CrossRef] [PubMed]
- Labbé, A.; Gabison, E.; Brignole-Baudouin, F.; Riancho, L.; Menashi, S.; Baudouin, C. Increased extracellular matrix metalloproteinase inducer (EMMPRIN) expression in the conjunctival epithelium exposed to antiglaucoma treatments. Curr. Eye Res. 2015, 40, 40–47. [Google Scholar] [CrossRef] [PubMed]
- Nedoszytko, B.; Lange, M.; Sokołowska-Wojdyło, M.; Renke, J.; Trzonkowski, P.; Sobjanek, M.; Szczerkowska-Dobosz, A.; Niedoszytko, M.; Górska, A.; Romantowski, J.; et al. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. Postepy Dermatol. Alergol. 2017, 34, 405–417. [Google Scholar] [CrossRef]
- Borcherding, N.; Voigt, A.P.; Liu, V.; Link, B.K.; Zhang, W.; Jabbari, A. Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression. Clin. Cancer Res. 2019, 25, 2996–3005. [Google Scholar] [CrossRef]
- Geng, J.; Chen, R.; Yang, F.F.; Lin, P.; Zhu, Y.M.; Fu, X.; Wang, K.; Feng, Z.; Wu, J.; Zhang, H.; et al. CD98-induced CD147 signaling stabilizes the Foxp3 protein to maintain tissue homeostasis. Cell Mol. Immunol. 2021, 18, 2618–2631. [Google Scholar] [CrossRef]
- Geng, J.J.; Tang, J.; Yang, X.M.; Chen, R.; Zhang, Y.; Zhang, K.; Miao, J.L.; Chen, Z.N.; Zhu, P. Targeting CD147 for T to NK Lineage Reprogramming and Tumor Therapy. eBioMedicine 2017, 20, 98–108. [Google Scholar] [CrossRef] [PubMed]
- Solstad, T.; Bains, S.J.; Landskron, J.; Aandahl, E.M.; Thiede, B.; Taskén, K.; Torgersen, K.M. CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells. Blood 2011, 118, 5141–5151. [Google Scholar] [CrossRef] [PubMed]
- Kachikwu, E.L.; Iwamoto, K.S.; Liao, Y.P.; DeMarco, J.J.; Agazaryan, N.; Economou, J.S.; McBride, W.H.; Schaue, D. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 1128–1135. [Google Scholar] [CrossRef] [PubMed]
Severity | CD147 TT | CD147 TA | CD147 AA | MAF | OR (95% CI) | Sensitivity Specificity Power Test | p |
---|---|---|---|---|---|---|---|
High (IIB, IIIA, IIIB) (N = 19) | 7 | 8 | 4 | 0.73 | 7.29 (1.48–35.92) for AA in high severity CTCL | 0.210 | 0.02 |
Low (parapsoriasis, IA, IB, IIA (N = 85) | 46 | 36 | 3 | 0.33 | 0.965 | ||
All (N = 104) | 53 | 44 | 7 | 0.39 | 0.542 |
Systemic Therapy | CD147 TT | CD147 TA | CD147 AA | MAF | OR (95% CI) | Sensitivity Specificity Power Test | p |
---|---|---|---|---|---|---|---|
No (N = 82) | 45 | 35 | 2 | 0.31 | 11.76 (2.1–65.79) for AA in patients treated with systemic therapy | 0.227 | 0.004 |
Yes (N = 22) | 8 | 9 | 5 | 0.76 | 0.976 | ||
All (N = 104) | 53 | 44 | 7 | 0.39 | 0.765 | ||
Interferon α | |||||||
No (N = 82) | 44 | 35 | 3 | 0.33 | 5.85 (1.20–28.47) for AA in patients treated with interferon α therapy | 0.182 | 0.03 |
Yes (N = 22) | 9 | 9 | 4 | 0.63 | 0.963 | ||
All (N = 104) | 53 | 44 | 7 | 0.39 | 0.460 | ||
Radiotherapy | |||||||
No (N = 96) | 50 | 42 | 4 | 0.35 | 13.8 (2.41–79.15) for AA in patients treated with radiotherapy | 0.375 | 0.009 |
Yes (N = 8) | 3 | 2 | 3 | 1.00 | 0.958 | ||
All (N = 104) | 53 | 44 | 7 | 0.39 | 0.954 |
Skin-Directed Therapy | HLA DRB1*1501CC | HLA DRB1*1501CT | MAF | OR (95% CI) | Sensitivity Specificity Power Test | p |
---|---|---|---|---|---|---|
No (N = 47) | 32 | 15 | 0.19 | 3.98 (1.40–11.33) for CC in patients treated with skin-directed therapy | 0.895 | 0.007 |
Yes (N = 57) | 51 | 6 | 0.06 | 0.319 | ||
All (N = 104) | 83 | 21 | 0.11 | 0.669 |
Severity | TTCC | TACC | AACC | TTCT | TACT | AACT | OR (95% CI) | Sensitivity Specificity Power Test | p |
---|---|---|---|---|---|---|---|---|---|
High (IIB, IIIA, IIIB) | 7 | 7 | 4 | 0 | 1 | 0 | 11.09 (1.86–65.90) for AACC in patients with high CTCL severity | 0.211 | 0.01 |
Low (parapsoriasis, IA, IB, IIA) | 35 | 28 | 2 | 11 | 8 | 1 | 0.976 | ||
All | 42 | 35 | 6 | 11 | 9 | 1 | 0.682 |
Systemic Therapy | TTCC | TACC | AACC | TTCT | TACT | AACT | OR (95% CI) | Sensitivity Specificity Powertest | p |
---|---|---|---|---|---|---|---|---|---|
No | 37 | 28 | 2 | 8 | 7 | 0 | 8.9 (1.51–52.33) for AACC in patients treated with systemic therapy | 0.182 | 0.02 |
Yes | 5 | 7 | 4 | 3 | 2 | 1 | 0.976 | ||
All | 42 | 35 | 6 | 11 | 9 | 1 | 0.618 | ||
Interferon α | |||||||||
No | 36 | 28 | 2 | 8 | 7 | 1 | 8.9 (1.51–52.33 for AACC in patients treated with interferon therapy | 0.182 | 0.02 |
Yes | 6 | 7 | 4 | 3 | 2 | 0 | 0.976 | ||
All | 42 | 35 | 6 | 11 | 9 | 1 | 0.618 | ||
Radiotherapy | |||||||||
No | 40 | 34 | 3 | 10 | 8 | 1 | 18.6 (2.97–116.64) for AACC in patients treated with radiotherapy | 0.375 | 0.006 |
Yes | 2 | 1 | 3 | 1 | 1 | 0 | 0.976 | ||
All | 42 | 35 | 6 | 11 | 9 | 1 | 0.964 | ||
Skin-directed therapy | |||||||||
No | 12 | 17 | 3 | 6 | 8 | 1 | 0.08 (0.01–0.72) for TACT in patients treated with skin-directed therapy | 0.982 | 0.007 |
Yes | 30 | 18 | 3 | 5 | 1 | 0 | 0.170 | ||
All | 42 | 35 | 6 | 11 | 9 | 1 | 0.644 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vašků, V.; Fialová, P.; Vašků, A. New Genetic Markers of Skin T-Cell Lymphoma Treatment. Genes 2024, 15, 358. https://doi.org/10.3390/genes15030358
Vašků V, Fialová P, Vašků A. New Genetic Markers of Skin T-Cell Lymphoma Treatment. Genes. 2024; 15(3):358. https://doi.org/10.3390/genes15030358
Chicago/Turabian StyleVašků, Vladimír, Petra Fialová, and Anna Vašků. 2024. "New Genetic Markers of Skin T-Cell Lymphoma Treatment" Genes 15, no. 3: 358. https://doi.org/10.3390/genes15030358
APA StyleVašků, V., Fialová, P., & Vašků, A. (2024). New Genetic Markers of Skin T-Cell Lymphoma Treatment. Genes, 15(3), 358. https://doi.org/10.3390/genes15030358